Partner Jacqueline Berman was quoted in a PharmaVoice article discussing the recent cuts to the FDA’s workforce, its impacts on the drug development process, and how it has hit everyone differently.
Jacqueline noted “If [delays] are happening, they’re happening on an individual, case-by-case basis, because different teams were impacted in different ways.”